136 related articles for article (PubMed ID: 24737408)
1. Interferon beta assessment in non-Chinese and Chinese subjects: pharmacokinetics and pharmacodynamic activity of an endogenous cytokine are not race dependent.
Rogge MC; Liu Y; Galluppi GR
J Clin Pharmacol; 2014 Oct; 54(10):1153-61. PubMed ID: 24737408
[TBL] [Abstract][Full Text] [Related]
2. Interferon beta-1a in relapsing multiple sclerosis: four-year extension of the European IFNbeta-1a Dose-Comparison Study.
Clanet M; Kappos L; Hartung HP; Hohlfeld R;
Mult Scler; 2004 Apr; 10(2):139-44. PubMed ID: 15124757
[TBL] [Abstract][Full Text] [Related]
3. An open-label safety and drug interaction study of natalizumab (Antegren) in combination with interferon-beta (Avonex) in patients with multiple sclerosis.
Vollmer TL; Phillips JT; Goodman AD; Agius MA; Libonati MA; Giacchino JL; Grundy JS
Mult Scler; 2004 Oct; 10(5):511-20. PubMed ID: 15471366
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and pharmacodynamics of peginterferon beta-1a in patients with relapsing-remitting multiple sclerosis in the randomized ADVANCE study.
Hu X; Cui Y; White J; Zhu Y; Deykin A; Nestorov I; Hung S
Br J Clin Pharmacol; 2015 Mar; 79(3):514-22. PubMed ID: 25265472
[TBL] [Abstract][Full Text] [Related]
5. [Pharmacological and clinical profile of IFNbeta-1a (Avonex IM Injection Syringe 30 microg].
Sumino R
Nihon Yakurigaku Zasshi; 2007 Mar; 129(3):209-17. PubMed ID: 17379973
[No Abstract] [Full Text] [Related]
6. Efficacy and tolerability of intramuscular interferon beta-1a compared with subcutaneous interferon beta-1a in relapsing MS: results from PROOF.
Minagara A; Murray TJ;
Curr Med Res Opin; 2008 Apr; 24(4):1049-55. PubMed ID: 18315940
[TBL] [Abstract][Full Text] [Related]
7. Intramuscular interferon beta-1a in chronic inflammatory demyelinating polyradiculoneuropathy.
Hughes RA; Gorson KC; Cros D; Griffin J; Pollard J; Vallat JM; Maurer SL; Riester K; Davar G; Dawson K; Sandrock A;
Neurology; 2010 Feb; 74(8):651-7. PubMed ID: 20177118
[TBL] [Abstract][Full Text] [Related]
8. COMPARE: Pharmacokinetic profiles of subcutaneous peginterferon beta-1a and subcutaneous interferon beta-1a over 2 weeks in healthy subjects.
Hu X; Shang S; Nestorov I; Hasan J; Seddighzadeh A; Dawson K; Sperling B; Werneburg B
Br J Clin Pharmacol; 2016 Aug; 82(2):380-8. PubMed ID: 27060836
[TBL] [Abstract][Full Text] [Related]
9. An open-label, multicenter study to evaluate the safe and effective use of the single-use autoinjector with an Avonex® prefilled syringe in multiple sclerosis subjects.
Phillips JT; Fox E; Grainger W; Tuccillo D; Liu S; Deykin A
BMC Neurol; 2011 Oct; 11():126. PubMed ID: 21999176
[TBL] [Abstract][Full Text] [Related]
10. Intramuscular interferon beta-1a is effective in Japanese patients with relapsing-remitting multiple sclerosis: a pre-treatment versus treatment comparison study of gadolinium-enhanced MRI brain lesions.
Saida T; Itoyama Y; Tashiro K; Kira J; Hao Q;
Mult Scler; 2012 Dec; 18(12):1782-90. PubMed ID: 22492130
[TBL] [Abstract][Full Text] [Related]
11. Effect of statins on clinical and molecular responses to intramuscular interferon beta-1a.
Rudick RA; Pace A; Rani MR; Hyde R; Panzara M; Appachi S; Shrock J; Maurer SL; Calabresi PA; Confavreux C; Galetta SL; Lublin FD; Radue EW; Ransohoff RM
Neurology; 2009 Jun; 72(23):1989-93. PubMed ID: 19506220
[TBL] [Abstract][Full Text] [Related]
12. The effects of intramuscular interferon beta-Ia in patients at high risk for development of multiple sclerosis: a post hoc analysis of data from CHAMPS.
O'Connor P;
Clin Ther; 2003 Nov; 25(11):2865-74. PubMed ID: 14693310
[TBL] [Abstract][Full Text] [Related]
13. Weekly IM interferon beta-1a in multiple sclerosis patients over 50 years of age.
Lampl C; You X; Limmroth V
Eur J Neurol; 2012 Jan; 19(1):142-8. PubMed ID: 21718390
[TBL] [Abstract][Full Text] [Related]
14. Differing immunogenic potentials of interferon beta preparations in multiple sclerosis patients.
Gneiss C; Tripp P; Reichartseder F; Egg R; Ehling R; Lutterotti A; Khalil M; Kuenz B; Mayringer I; Reindl M; Berger T; Deisenhammer F
Mult Scler; 2006 Dec; 12(6):731-7. PubMed ID: 17263000
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of injectable disease-modifying therapies for the treatment of relapsing forms of multiple sclerosis in Spain.
Dembek C; White LA; Quach J; Szkurhan A; Rashid N; Blasco MR
Eur J Health Econ; 2014 May; 15(4):353-62. PubMed ID: 23615954
[TBL] [Abstract][Full Text] [Related]
16. Long-term benefits of early and high doses of interferon beta-1a treatment in relapsing-remitting multiple sclerosis.
Chofflon M; Ben-Amor AF
Clin Neurol Neurosurg; 2002 Jul; 104(3):244-8. PubMed ID: 12127662
[No Abstract] [Full Text] [Related]
17. Early MRI activity predicts treatment nonresponse with intramuscular interferon beta-1a in clinically isolated syndrome.
Kinkel RP; Simon JH; O'Connor P; Hyde R; Pace A
Mult Scler Relat Disord; 2014 Nov; 3(6):712-9. PubMed ID: 25891550
[TBL] [Abstract][Full Text] [Related]
18. Randomized study of once-weekly interferon beta-1la therapy in relapsing multiple sclerosis: three-year data from the OWIMS study.
Freedman MS; Francis GS; Sanders EA; Rice GP; O'Connor P; Comi G; Duquette P; Metz L; Murray TJ; Bouchard JP; Abramsky O; Pelletier J; O'Brien F; ;
Mult Scler; 2005 Feb; 11(1):41-5. PubMed ID: 15732265
[TBL] [Abstract][Full Text] [Related]
19. Comparative injection-site pain and tolerability of subcutaneous serum-free formulation of interferonβ-1a versus subcutaneous interferonβ-1b: results of the randomized, multicenter, Phase IIIb REFORMS study.
Singer B; Bandari D; Cascione M; LaGanke C; Huddlestone J; Bennett R; Dangond F;
BMC Neurol; 2012 Dec; 12():154. PubMed ID: 23216674
[TBL] [Abstract][Full Text] [Related]
20. Randomized study of interferon beta-1a, low-dose azathioprine, and low-dose corticosteroids in multiple sclerosis.
Havrdova E; Zivadinov R; Krasensky J; Dwyer MG; Novakova I; Dolezal O; Ticha V; Dusek L; Houzvickova E; Cox JL; Bergsland N; Hussein S; Svobodnik A; Seidl Z; Vaneckova M; Horakova D
Mult Scler; 2009 Aug; 15(8):965-76. PubMed ID: 19465443
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
